Gap compensation during accelerated hypofractionated radiotherapy in head and neck cancer
Authors:
- 1 March 2008
- journal article
- research article
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 7 (1) , 31-38
Abstract
Introduction: In squamous-cell carcinoma (SCC) of the head and neck, unplanned gaps risk prolongation of the overall treatment time (OTT) and reduction in tumour control. This audit determines whether further acceleration can safely be employed to compensate for missed treatments during accelerated hypofractionated radiotherapy. Methods: Patients receiving accelerated hypofractionated radiotherapy for SCC of the head and neck were prospectively audited. Outcome measures were OTT, degree of compensation and acute toxicity determined by incidence of grade 3 mucositis, prolonged grade 3 mucositis, grade 3 dysphagia and pain. Results: In the 87 patients identified, the dose administered was 55 Gy in 20 fractions (81 patients), 50 Gy in 20 fractions (1 patient) and 50 Gy in 16 fractions (5 patients). Of those patients receiving 20 fractions, 94% completed within 28 days. Grade 3 mucositis was seen in 56 patients (64%). Compensating for unplanned gaps did not result in any significant increase in toxicity. Administering 6 fractions/week, as compensation, was associated with a lower pain score (p = 0.003) as was receiving 2 fractions on the same day (p = 0.0004). Conclusions: Accelerated hypofractionation is tolerable with most patients completing treatment within the planned OTT. When unplanned gaps occur, then compensation by further acceleration is possible.Keywords
This publication has 23 references indexed in Scilit:
- Results of a UK survey on methods for compensating for unscheduled treatment interruptions and errors in treatment deliveryBritish Journal of Radiology, 2007
- Hypofractionated Accelerated Radiotherapy With Concurrent Chemotherapy For Locally Advanced Squamous Cell Carcinoma of the Head and NeckInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neckRadiotherapy and Oncology, 2004
- Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trialThe Lancet, 2003
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- The Correlation of Acute Toxicity and Late Rectal Injury in Radiotherapy for Cervical Carcinoma: Evidence Suggestive of Consequential Late Effect (CQLE)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicityRadiotherapy and Oncology, 1996
- A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapyClinical Oncology, 1996
- Planned and unplanned gaps in radiotherapy: the importance of gap position and gap durationRadiotherapy and Oncology, 1994
- The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapyRadiotherapy and Oncology, 1992